AAAAAA

   
Results: 1-8 |
Results: 8
A phase I study of Onyx-015, an ELB-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (vol 6, pg 798, 2000)
Authors: Ganly, I Kirn, D Eckhardt, SG Rodriguez, GI Soutar, DS Otto, R Robertson, AG Park, O Gulley, ML Heise, C VonHoff, DD Kaye, SB
Citation: I. Ganly et al., A phase I study of Onyx-015, an ELB-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (vol 6, pg 798, 2000), CLIN CANC R, 7(3), 2001, pp. 754-754
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
Authors: Rothenberg, ML Kuhn, JG Schaaf, LJ Rodriguez, GI Eckhardt, SG Villalona-Calero, MA Rinaldi, DA Hammond, LA Hodges, S Sharma, A Elfring, GL Petit, RG Locker, PK Miller, LL von Hoff, DD
Citation: Ml. Rothenberg et al., Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks, ANN ONCOL, 12(11), 2001, pp. 1631-1641
A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intramorally to patients with recurrent head and neck cancer (vol 6, pg 798, 2000)
Authors: Ganly, I Kirn, D Eckhardt, SG Rodriguez, GI Soutar, DS Otto, R Robertson, AG Park, O Gulley, ML Heise, C VonHoff, DD Kaye, SB
Citation: I. Ganly et al., A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intramorally to patients with recurrent head and neck cancer (vol 6, pg 798, 2000), CLIN CANC R, 6(9), 2000, pp. 3797-3797
A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
Authors: Ganly, I Kirn, D Eckhardt, SG Rodriguez, GI Soutar, DS Otto, R Robertson, AG Park, O Gulley, ML Heise, C Von Hoff, DD Kaye, SB
Citation: I. Ganly et al., A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer, CLIN CANC R, 6(3), 2000, pp. 798-806
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors
Authors: Diab, SG Baker, SD Joshi, A Burris, HA Cobb, PW Villalona-Calero, RA Eckhardt, SG Weiss, GR Rodriguez, GI Drengler, R Kraynak, M Hammond, L Finizio, M Von Hoff, DD Rowinsky, EK
Citation: Sg. Diab et al., A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors, CLIN CANC R, 5(2), 1999, pp. 299-308
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin)
Authors: Gerrits, CJH Schellens, JHM Burris, H Eckardt, JR Planting, AST van der Burg, MEL Rodriguez, GI Loos, WJ van Beurden, V Hudson, I Von Hoff, DD Verweij, J
Citation: Cjh. Gerrits et al., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin), CLIN CANC R, 5(1), 1999, pp. 69-75
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors
Authors: Drengler, RL Kuhn, JG Schaaf, LJ Rodriguez, GI Villalona-Calero, MA Hammond, LA Stephenson, JA Hodges, S Kraynak, MA Staton, BA Elfring, GL Locker, PK Miller, LL Von Hoff, DD Rothenberg, ML
Citation: Rl. Drengler et al., Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors, J CL ONCOL, 17(2), 1999, pp. 685-696
Phase trial of docetaxel for cholangiocarcinoma
Authors: Pazdur, R Royce, ME Rodriguez, GI Rinaldi, DA Patt, YZ Hoff, PM Burris, HA
Citation: R. Pazdur et al., Phase trial of docetaxel for cholangiocarcinoma, AM J CL ONC, 22(1), 1999, pp. 78-81
Risultati: 1-8 |